Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report

Breast cancer (BC) with overexpression of human epidermal growth factor receptor 2 (HER2) is closely associated with an elevated risk of multiple distant metastases and unfavorable prognosis. Disitamab Vedotin (RC48) is a newly developed antibody-drug conjugate targeting HER2, which is comprised of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qifeng, He, Lina, Luo, Jing, Jin, Wen, Xu, Yingchun, Wang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404700/
https://www.ncbi.nlm.nih.gov/pubmed/36039062
http://dx.doi.org/10.3892/ol.2022.13459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404700/
https://www.ncbi.nlm.nih.gov/pubmed/36039062
http://dx.doi.org/10.3892/ol.2022.13459

Ejemplares similares